ValuEngine lowered shares of Misonix (NASDAQ:MSON) from a buy rating to a hold rating in a research note released on Friday.
A number of other equities research analysts have also recently weighed in on MSON. Canaccord Genuity started coverage on Misonix in a research note on Friday, August 24th. They issued a buy rating and a $24.00 price target on the stock. TheStreet cut Misonix from a c rating to a d+ rating in a research report on Friday, September 7th. Finally, Craig Hallum began coverage on Misonix in a research report on Tuesday, September 11th. They set a buy rating and a $28.00 price objective on the stock.
MSON opened at $16.50 on Friday. Misonix has a 1-year low of $8.25 and a 1-year high of $21.43.
In other Misonix news, VP Christopher H. Wright sold 10,000 shares of the stock in a transaction on Wednesday, November 28th. The stock was sold at an average price of $16.31, for a total transaction of $163,100.00. Following the transaction, the vice president now owns 10,000 shares in the company, valued at approximately $163,100. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Joseph J. Brennan sold 8,357 shares of the stock in a transaction on Thursday, December 6th. The stock was sold at an average price of $15.91, for a total value of $132,959.87. Following the transaction, the vice president now owns 5,649 shares in the company, valued at approximately $89,875.59. The disclosure for this sale can be found here. Insiders have sold a total of 18,958 shares of company stock worth $305,838 in the last quarter. Company insiders own 24.60% of the company’s stock.
A number of hedge funds have recently bought and sold shares of MSON. Wells Fargo & Company MN increased its position in Misonix by 1,487.5% during the 3rd quarter. Wells Fargo & Company MN now owns 6,350 shares of the medical equipment provider’s stock worth $117,000 after buying an additional 5,950 shares during the period. Acadian Asset Management LLC increased its position in Misonix by 388.8% during the 3rd quarter. Acadian Asset Management LLC now owns 8,212 shares of the medical equipment provider’s stock worth $152,000 after buying an additional 6,532 shares during the period. BlackRock Inc. increased its position in Misonix by 39.0% during the 2nd quarter. BlackRock Inc. now owns 25,660 shares of the medical equipment provider’s stock worth $318,000 after buying an additional 7,203 shares during the period. Manatuck Hill Partners LLC bought a new position in Misonix during the 3rd quarter worth $329,000. Finally, Nordea Investment Management AB bought a new position in Misonix during the 3rd quarter worth $649,000. Hedge funds and other institutional investors own 15.93% of the company’s stock.
Misonix Company Profile
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
Recommended Story: S&P 500 Index
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.